Abstract. Global DNA hypomethylation potentially leading to pro-atherogenic gene expression occurs in atherosclerotic lesions. However, limited information is available on the genomic location of hypomethylated sequences. We present a microarray-based survey of the methylation status of CpG islands (CGIs) in 45 human atherosclerotic arteries and 16 controls. Data from 10,367 CGIs revealed that a subset (151 or 1.4%) of these was hypermethylated in control arteries. The vast majority (142 or 94%) of this CGI subset was found to be unmethylated or partially methylated in atherosclerotic tissue, while only 17 of the normally unmethylated CGIs were hypermethylated in the diseased tissue. The most common functional classes among annotated genes adjacent to or containing differentially methylated CGIs, were transcription (23%) and signalling factors (16%). The former included HOX members, PROX1, NOTCH1 and FOXP1, which are known to regulate key steps of atherogenesis. Expression analysis revealed differential expression of all CGI-associated genes analysed. Sequence analysis identified novel DNA motifs with regulatory potential, associated with differentially methylated CGIs. This study is the first large-scale analysis of DNA methylation in atherosclerosis. Our data suggest that aberrant DNA methylation in atherosclerosis affects the transcription of critical regulatory genes for the induction of a pro-atherogenic cellular phenotype.
Introduction
Atherosclerosis risk is in part determined by dietary and lifestyle-related factors, suggesting that diet-and environment-gene interactions are among the key phenomena in the aetiology and natural history of the disease. Epigenetics offers in principle a molecular model of such interactions, by envisioning that dietary and environmental risk factors modulate gene expression by laying down aberrant DNA methylation and histone post-translational modification patterns, which in turn convert permissive, relaxed chromatin into non-permissive, compact chromatin, or vice versa, depending on the specific gene involved (1) . Accordingly, elegant animal models offer proof of principle for the idea that simple dietary interventions can have a significant impact on DNA methylation (2) . As for atherosclerosis, potentially predisposing abnormal DNA methylation patterns have been detected in animal models prior to the appearance of vascular lesions (3) . Furthermore, human and animal studies consistently indicate that global DNA hypomethylation accompanies advanced atherosclerosis (3, 4) . Importantly, 2 recent human studies have indicated that circulating levels of inflammation markers and exposure to environmental risk factors for atherosclerosis were associated with hypomethylation of highly repeated elements of leukocyte DNA (5, 6) . Identifying the sequences undergoing demethylation in atherosclerosis could provide important insights into the molecular mechanisms of atherogenesis and possibly of diet-or environment-gene interactions (7) . We therefore conducted an array-based analysis of the DNA methylation status of CpG islands (CGIs) in control (CAs) and atherosclerotic arteries (AAs). CGIs are discrete sequences present both in intra-and intergenic regions, including the promoters of about half of the human genes (8) . The observation that promoter CGI hypermethylation is usually associated with gene silencing in a number of physiological situations including cancer, suggests the pivotal role of CGI DNA methylation in transcription regulation (9) . Our study is the first large-scale description of sequences undergoing aberrant DNA methylation in atherosclerosis.
Materials and methods
Tissue samples. All relevant procedures were approved by the local ethics committee. Atherosclerotic artery samples were obtained from ischaemic cardiopathy patients undergoing revascularization surgery. Although the atherosclerotic lesions were not histologically classified for severity, our samples consisted of advanced stage lesions, according to surgery recommendations. A fragment of the coronary artery at the lesion site, including the lesion and underlying media, was obtained during the application of the aorta-coronary bridge. The control samples were aortic fragments from patients undergoing aortic valve replacement surgery and with no coronary atherosclerotic lesions, as was indicated by cardiac catheterization and confirmed during surgery. Diabetes was the only exclusion criterion for both groups. Tissue samples were collected in RNAlater (Ambion) and transferred to -20˚C within 2 h from surgery.
Array analysis. Two pools of DNA were prepared, representing equal amounts of the control (n=16) or atherosclerotic (n=45) artery samples, respectively. The 2 groups did not differ in gender (2:1 male:female ratio) or age (22-79 years, p>0.05). Hypermethylated DNA fractions were prepared by digestion with the methylation-sensitive enzyme, HpaII, and HpaII-end containing (i.e. unmethylated) fragments were eliminated by exonuclease III treatment according to the method described by Shann et al (10) , followed by amplification with the WGA system (Sigma). Reference DNA was prepared by mock digestions in which HpaII was omitted. Primers were eliminated by passage through MinElute columns (Qiagen). Array analysis (labelling, hybridization and raw data generation) was performed at the UHN Microarray Centre, Toronto, Canada. The microarray used (HCGI15K; UHN; www.microarrays.ca) was a singlespotted array containing 14,923 CpG-island clones including the HCGI8.1K set of UHN and a new 6.8K set generated by sequence-specific primers targeting potential CpG-island clones that are currently not in any of the UHN collections. BLAT-annotated clones with overlapping sequences >20% of either clone were considered as duplicates and excluded. Clones with internal repeat sequences, with no or >1 BLAT hits and those mapped to the mitochondrial chromosome (M), were also excluded. Two series of arrays in triplicate, one for the control and the other for the atherosclerotic samples, were co-hybridized with Alexa647-labelled (red) HpaII-digested DNA and Alexa555-labelled (green) reference DNA. The background-subtracted Alexa647 and Alexa555 intensities were normalized to the overall median Alexa555 intensity calculated on all the arrays, and the log 2 of the Alexa647/Alexa555 ratio was calculated for each individual array as previously reported (10) . Comparisons between the 2 array groups were conducted by ANOVA. Array data have been deposited into the GEO database (www.ncbi.nlm.nih.gov/ projects/geo/) with accession no. GSE15552.
Array data validation. Array data for 10 differentially methylated CGIs were validated by methylation-sensitive PCR (MS-PCR) in 10 more samples from each group with the same characteristics as the ones used for the array analysis. In brief, 10 ng DNA were digested with 1 U McrBC overnight and a 200-300 bp CGI portion was amplified by 35-cycle PCRs. Primers were designed with BiSearch (bisearch.enzim.hu) and their sequences are available upon request (11) . Band intensity was quantified with Quantity One software (Bio-Rad) and normalized to the median intensity of the PCR products of the mock-treated DNA (input) made equal to the arbitrary value of 1. MS-PCRs for each gene were run and analysed on the same gel to reduce variability.
Gene expression analysis. RNA was extracted with the RNeasy system (Qiagen) and cDNA was prepared from 3 μg RNA pooled from the same 10 samples used for MS-PCR, using the Access RT-PCR system (Promega). For each gene, one-fiftieth of cDNA was amplified by using the LightCycler FastStart DNA Master PLUS SYBR Green I (Roche) according to the manufacturer's instructions in a LightCycler 1.5 machine (Roche), with primers designed in qPrimerDepot (primerdepot.nci.nih.gov). Primer sequences are available upon request. Ct values were calculated using a fluorescence value equal to twice the baseline as the threshold. The expression was normalized by calculating the ratio between the Ct of a sample and the average Ct for GAPDH in the same group CAs or AAs.
Bioinformatics. For bioinformatics analysis, CGI annotations were as provided by the array supplier and were based on NCBI UniGene human build 217 and UCSC human build hg18. Genomic localization was determined with the NCBI Map Viewer resource (www.ncbi.nlm.nih.gov). CG content and CpG density (CpG count/CGI length ratio) were determined with the EMBOSS CG and CpG report tools (oz.ifc.unam.mx/EMBOSS). Gene functions were deduced according to the categories on the Gene Ontology database (www.geneontology.org). DNA motif search was conducted with MEME software (meme.sdsc.edu) using default parameters (12) . DNA motifs were compared against the databases of known protein-binding DNA sequences, namely the TRANSFAC and JASPAR core databases, using TOMTOM (meme.nbcr.net/meme4_1/cgi-bin/tomtom.cgi).
Results

CGI methylation status in CAs and
AAs. Our array-based survey yielded reliable data on the methylation status for 10,367 CGIs. We classified CGIs as unmethylated if the Alexa647/Alexa555 ratio was <0.3, or if log 2 Alexa647/ Alexa555 (log 2 r/g) was <-1.6, representing an excess hybridized reference DNA (i.e. not HpaII digested) compared to filtered DNA. CGIs were considered to be hypermethylated if the Alexa647/Alexa555 ratio was >3, corresponding to log 2 r/g >1. 6 . Intermediate values were considered as partial hypo-or hypermethylation (Fig. 1A) .
In accordance with the well established notion that the vast majority of CGIs are unmethylated (8) , most of the (9,085 or 87.6%) CA CGIs fell within the unmethylated class and accordingly, the overall median CA CGI log 2 r/g was -2.4. In contrast, the hypermethylated CGIs were a minority (151 or 1.4%) in this group. In order to corroborate the array results, the methylation status of 10 randomly chosen un-or hypermethylated CA CGIs was verified by MS-PCR in the DNA pool used for the hybridizations (Fig. 1B) .
The comparison of the CGI methylation status between CAs and AAs revealed significant (p<0.01) changes. Of the 151 normally hypermethylated CGIs, 142 (or 94%) were found to be unmethylated or in an intermediate methylation status in AAs (Fig. 1A) . Conversely, only 17 of the CGIs that were unmethylated or intermediately methylated in CAs, were hypermethylated in AAs. We validated the methylation status of 10 CGIs differentially methylated between AAs and CAs (DM-CGIs) adjacent to relevant genes by MS-PCR in 10 more age-and gender-paired samples not included in the array analysis ( Fig. 2A) . Validation examples of DM-CGI methylation status are shown in Fig. 2B . Further characterization was carried out of those differentially methylated CGIs that showed the most extreme changes in DNA methylation, i.e. were hypermethylated in one group (log 2 r/g >1.6) and incompletely methylated or unmethylated (i.e. showing an Alexa647/Alexa555 ratio <0.75, corresponding to log 2 r/g <-0.4) in the other group, with a p-value of <0.01. Excluding BLAT-unmatched clones, 45 CGIs hypermethylated in CAs and 10 in AAs met these criteria. These CGIs will be referred to as DM-CGIs.
Genomic location of DM-CGIs.
A recent study of normal, non-vascular human tissues has shown that CGIs with tissuespecific methylation status are found in specific genomic locations, thus providing insights on the mechanisms and transcriptional impact of differential methylation (13) . In order to assess whether comparable patterns occur in atherosclerosis, we analysed the genomic locations of DM-CGIs (n=45) and non-DM-CGIs that were hypermethylated in both CAs and AAs (HH-CGIs; n=8). Twenty-nine DM-CGIs were intragenic and 26 were intergenic, whereas the majority of HH-CGIs (6 out of 8) was intragenic. These CGIs differed in their distribution (Fig. 3) . DM-CGIs unmethylated in AAs tended to be localized preferentially in promoters (i.e. 5' UTR, TSS and 1.0 kb upstream to the latter) and first introns. In contrast, DM-CGIs hypermethylated in AAs showed a broader distribution encompassing 5' and middle third gene portions (p<0.03 in comparison with the latter group). Intragenic HH-CGIs, however, were preferentially positioned at middle third gene portions (p<0.02 in comparison with either DM-CGI class distribution). All 3 CGI classes were similarly represented at 3' UTR regions (Fig. 3) . Of the 20 DMCGIs and HH-CGIs that were not within promoters or 3' UTR regions, the vast majority (17 or 85%) was located in introns rather than in protein coding sequences.
As for intergenic DM-CGIs, their distance from flanking genes varied (i.e. 1.2-120 kb). Of this CGI group, 14 (or 54%) were the only array-represented CGIs positioned between the respective up-or downstream genes, while 11 were the closest CGIs to either the respective down-or upstream gene. Furthermore, DM-CGIs that were unmethylated in AAs were in average ~100-fold more distant from downstream or upstream genes than DM-CGIs hypermethylated in AAs or intergenic HH-CGIs (350.5+678.1, 2.6+2.4 and 2.7+2.2 kb, respectively; p<0.001).
Identity and expression of DM-CGI-associated genes.
The functional classification of annotated genes upstream or downstream to, or containing DM-CGIs, revealed several gene functions, with a bias towards transcription factors (TFs), representing the most numerous class, followed by signalling factors and genes involved in organelle homeostasis (Table I) . A description of the DM-CGI genomic location and adjacent annotated genes is presented in Table II . Furthermore, we analysed the expression of TFs and atherosclerosis-related genes adjacent to, or containing the 10 DMCGIs for which we validated the methylation status, by quantitative RT-PCR in the same 10 samples used for MS-PCR (Fig. 4 , graphs on the right). A schematic representation of the regions containing validated DM-CGIs is shown in Fig. 4 , left side. Differential DNA methylation coincided with changes in expression in all the cases analyzed (p<0.03 in comparison with normalized Ct). The methylation status of several DM-CGIs was inversely related with gene expression. Two intergenic DM-CGIs located in the HOX TF clusters were one notable example. One DM-CGI was located downstream to HOXD10 between HOXD4 and HOXD8 in chromosome 2 and was hypermethylated in AAs, while the other was located in a region of chromosome 12 including HOXC9, HOXC10 and HOXC11, and was unmethylated in AAs. The expression of HOXC9, HOXC10 and HOXD10 was inversely related to the methylation status of the associated DM-CGI ( Fig. 4A and B) . The same pattern was observed in a DM-CGI unmethylated in AAs occupying the EGFL7 promoter and downstream to the TF gene, NOTCH1 (Fig. 4C  and D) . Two other DM-CGIs lay ~1 Mb apart in a region of chromosome 1 in the vasohibin 2 (VASH2) promoter and upstream to PROX1, another member of homeobox TFs, respectively ( Fig. 4E and F) . Hypermethylation of DM-CGIs in AAs coincided with transcriptional down-regulation of the latter 2 genes. Similarly, hypomethylation of a 3' UTR DM-CGI coincided with up-regulation of the S100B gene and promoter hypermethylation was associated with MBD2 down-regulation in AAs (Fig. 4G and H) . In contrast with the above patterns, hypomethylation of 2 intragenic DM-CGIs was associated with expression down-regulation in the case of smoothelin (SMTN) and TF FOXP1 (Fig. 4I and J) .
Furthermore, we confirmed the methylation status of 3 DM-CGIs previously reported to have a hypermethylation tendency in atherosclerosis (i.e. in the 5' region of ESR2, FADS2 and TFPI2) (14) (15) (16) . Log 2 r/g values in CAs and AAs were -2.72, -1.40 for ESR2, and -3.14, -2.18 for FADS2, respectively, with a p-value of <0.05 in both cases. Corresponding values for TFPI2 were -2.27 and -2.11 with no significant difference, and were in line with the observation that hypermethylation at that gene was present in a minority of lesions (16) . Other promoters previously studied in atherosclerosis were not represented in the arrays used here.
Bioinformatic analysis of DM-CGI.
We searched for sequence features in DM-CGIs and HH-CGIs that could yield further insights into the mechanisms of CGI differential methylation. The comparison of CGI size, CG content and CpG density (no. of CpG to CGI length ratio), a parameter shown to be related with CGI methylation status in somatic cells (17) , did not reveal any significant difference. Furthermore, we screened for DNA motifs unique for any CGI class in 4 kb-sequences centered at the CGI midpoint. The presence of class-specific DNA motifs could signal the possible involvement of DNA-binding factors in the establishment of differential DNA methylation. The MEME software yielded a 29-bp motif (DMM) that was present in 55.5% of the DMCGIs unmethylated in AAs (E=2.2e-118) but absent in the DM-CGIs hypermethylated in AAs or the HH-CGIs (Fig. 5A) . The lack of DMM detection in HH-CGIs was not due to 
-----------------------------------------------------------------------------------------------------
a If multiple functions have been reported for a gene, the function relevant to atherogenesis is listed. Table II . Continued. sample size, as repeated analyses of randomly chosen groups of n=8 DM-CGIs always identified the motif. Neither the DMM presence nor copy number correlated with DM-CGI size, but the DMM copy number was weakly correlated with CpG density (r=0.42, p<0.02). DMM was not preferentially associated with intra-or intergenic DM-CGIs, but the DMMassociated DM-CGIs were on average ~10-fold closer to downstream genes than non-DMM-associated DM-CGIs (56.8±50.0 and 644.2±511.1 kb, respectively, p<0.03). Furthermore, we detected a candidate non-DM-CGI motif (non-DMM) present in 6 out of the 8 HH-CGIs but not present in any of the DM-CGIs (E=3.3e-14; Fig. 5B ). Both DMM and non-DMM were invariably located outside CGIs. The analysis of mouse CGIs with BLAST homology with DMMassociated DM-CGI revealed a conserved 5'-AGNNCAGG-3' sequence present in DMM, and a 5'-ACTCCAGNCTGGG-3' sequence present in non-DMM ( Fig. 5A and B) . Neither DMM nor non-DMM match any known binding site included in the TRANSFAC and JASPAR core databases. In addition, the MEME software yielded a 29-bp DNA motif present in 100% of the DM-CGIs hypermethylated in AAs and in 12 (or 26.6%) of the DM-CGIs unmethylated in AAs. This DNA motif shows homology with the Krox binding site according to the TRANSFAC database (p=8.6e-07; Fig. 5C ). The 2 DM-CGI-specific DNA motifs were not mutually exclusive, as 4 DMM-associated DM-CGIs also contained a putative Krox binding site. We also detected CT-and A-rich motifs previously reported in normally hypermethylated CGIs but these were not significantly over-represented in any CGI class analysed here (18) .
----------------------------------------------------------------------------------------------------- CGI clone Genomic location Within Upstream Downstream Average Average log 2 r/g CA log 2 r/g AA ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Discussion
By examining the DNA methylation status of ~10,000 CGIs in CAs and AAs, we hereby presented an initial largescale analysis of the epigenetic changes associated with cardiovascular disease. The analysis of CA CGI methylation showed that a small portion of autosomal, not imprinted geneassociated CGIs is hypermethylated, thus supporting previous suggestions that this DNA methylation pattern could be a general feature of somatic tissues (18, 19) . The vast majority of these normally hypermethylated CGIs is found unmethylated in AAs, indicating that this net CGI demethylation contributes to the global DNA hypomethylation observed in atherosclerotic tissues in previous studies (20) . DM-CGIs were located within or relatively close to a number of genes known to be involved in atherogenesis. Approximately 40% of the DM-CGI-associated genes were regulatory (i.e. TFs and signalling factors), in accordance with the idea that epigenetic changes are upstream events in the establishment of an atherosclerosis-specific gene expression pattern. In general, CGI differential methylation was associated with up-or down-regulation of genes implicated in angiogenesis, vascular smooth muscle cells (VSMCs) phenotype modulation and inflammation. One remarkable example was the opposite effects on HOXC and HOXD members, known to promote vascular remodelling and inhibit adult angiogenesis, respectively (22) . HOXCs located in physical proximity to a DM-CGI unmethylated in AAs were selectively expressed in AAs, whereas the precisely opposite pattern was observed in HOXD10. A recent study reported that aberrant homeobox CGI methylation is a frequent event in breast cancer, thus suggesting a partially overlapping epigenetic dysregulation of cell proliferation and migration in distinct diseases (23) . Furthermore, we observed activation of NOTCH1 and EGFL7, 2 inducers of angiogenesis that are physically associated with the same DM-CGI, and down-regulation of VASH2, an inhibitor of adult angiogenesis, in AAs (24) (25) (26) . It has also been reported that demethylation of the EGFL7 promoter activates miR-126, a pro-angiogenic micro-RNA transcribed from an EGFL7 intron (27) . Another landmark of atherogenesis is the transition of VSMC from a contractile, differentiated phenotype to a secretory, relatively immature one. This phenomenon is accompanied by a significant re-organization of organelles and secretory vesicles (28) . Accordingly, we observed downregulation of the differentiated VSMC marker, SMTN, in AAs, and organelle homeostasis and secretory genes were found associated with DM-CGIs (29) . As for inflammation, we observed down-regulation of FOXP1, a forkhead family TF shown to inhibit macrophage activation, and up-regulation of the AGE receptor ligand, S100B (30, 31) . Relatively few genes involved in chromatin structure regulation were associated with DM-CGIs and their role in atherogenesis is poorly understood. One exception is MBD2, representing a methylcytosine-binding protein that can be induced in cultured VSMCs by stimulation with homo-cysteine, an amino acid implicated in atherogenesis (32) .
The analysis of DM-CGI genomic location provided insights into the potential mechanisms of transcriptional control by CGI methylation. In the case of the 10 validated DM-CGIs, the methylation status of the intergenic or promoter DM-CGIs was inversely related with gene expression in accordance with the generally accepted role of DNA methylation in transcription regulation. In contrast, the opposite was observed between methylation and transcription for the intragenic DM-CGI-associated genes, FOXP1 and SMTN. This observation suggests that intragenic DNA methylation has a complex impact on gene expression as hinted at by previous studies on plants (33) . For all the validated intergenic DM-CGIs, differential CGI methylation was associated with changes in the expression of genes located as far as 120 kb and separated by up to 5 non-DM-CGIs from the relevant DM-CGI. This observation is reminiscent of the results of a previous study showing that regions of tissuespecific methylation are often distant from genes (34) . Thus, our data suggest the testable hypothesis that at least some DMCGIs could be important long-range epigenetic expression regulators.
Our data indicate that DM-CGIs and HH-CGIs show different intragenic distributions. DM-CGIs unmethylated in AAs and HH-CGIs are significantly more abundant in promoters and in the middle third introns of genes, respectively. These results differ from the ones of a recent largescale bioinformatics-based study including a wide range of non-vascular normal human tissues (13) . The authors showed that DM-CGIs are significantly more abundant in introns than in other gene compartments, while promoters preferentially include constitutively unmethylated CGIs. In the light of this data comparison, it is conceivable that during atherogenesis, the normal equilibrium between mechanisms that maintain selected (i.e. promoter-associated) CGIs in a constitutively unmethylated state, and other mechanisms establishing tissue-specific CGI hypermethylation is lost in favour of the former. Another difference between our studies is the lack of a substantial association of any DM-CGI or HH-CGI with protein coding regions in our samples. Further study is required to assess whether these discrepancies reflect distinct CGI methylation regulations in normal and diseased cells. Furthermore, our data do not show any significant preference for the inter-or intragenic location of DM-CGIs, whereas the study mentioned above indicates that DM-CGIs are mainly intragenic. Nevertheless, this likely reflects a bias against intergenic elements in the latter CGI collection (13) .
DM-CGI nucleotide composition analysis provided limited hints on the mechanisms of differential CGI methylation between AAs and CAs. CpG density did not correlate with the DM-or HH-CGI status, indicating that CGI demethylation in CAs is mechanistically distinct from the preferential demethylation of CpG-dense CGIs in somatic cells (13, 17) . The presence of CGI class-specific DNA motifs suggests that differential CGI methylation could be regulated by DNAbinding factor(s). As for the yet uncharacterized DMM motif, our data on the distance between DM-CGIs and adjacent annotated genes suggest that this DNA motif could regulate the DNA methylation of CGIs involved in relatively shortrange interactions with downstream genes. The functional significance of the over-representation of the DMM motif in high CpG density DM-CGIs is difficult to interpret, although it could be related to the preferential somatic demethylation of CpG-dense CGIs as mentioned above (13, 17) . The presence of putative Krox binding sites in a subset of DM-CGIs was expected, since early growth response TFs play a pivotal role in atherogenesis (35) . Nevertheless, Krox binding site-associated CGIs showed inconsistent DNA methylation changes between CAs and AAs, making it difficult to assign a straightforward epigenetic function to this motif.
One limitation of the present study was the cell type heterogeneity of AAs compared to CAs, which raises the possibility that at least some of the observed DM-CGI methylation and gene expression patterns were not established de novo in atherosclerosis but were pre-existent in nonvascular cells recruited to the lesion, such as monocytes, macrophages, lymphocytes and others. Nonetheless, at least in the case of validated DM-CGI, the sharp between-group differences in DNA methylation and expression levels suggests that the observed changes involved the majority of cells in AAs, thus including VSMCs and endothelial cells. Another study is currently in progress to identify cell typespecific epigenetic changes in vascular lesions.
